List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8663359/publications.pdf

Version: 2024-02-01



LAURA D WOOD

#	Article	lF	CITATIONS
1	The Impact of Clinical and Pathological Features on Intraductal Papillary Mucinous Neoplasm Recurrence After Surgical Resection. Annals of Surgery, 2022, 275, 1165-1174.	4.2	15
2	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. ELife, 2022, 11, .	6.0	6
3	Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer Discovery, 2022, 12, 692-711.	9.4	58
4	Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology, 2022, 163, 386-402.e1.	1.3	204
5	Cancerization of ducts in hilar cholangiocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , .	2.8	0
6	Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut, 2021, 70, 148-156.	12.1	139
7	Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 319-326.	2.8	16
8	Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic <i>KLF4</i> mutations predominantly in low-grade regions. Gut, 2021, 70, 928-939.	12.1	48
9	Pancreatic cancer pathology viewed in the light of evolution. Cancer and Metastasis Reviews, 2021, 40, 661-674.	5.9	7
10	Cell of Origin Influences Pancreatic Cancer Subtype. Cancer Discovery, 2021, 11, 660-677.	9.4	58
11	Pathology of intraductal papillary mucinous neoplasms. Langenbeck's Archives of Surgery, 2021, 406, 2643-2655.	1.9	6
12	Downregulation of 5â€hydroxymethylcytosine is an early event in pancreatic tumorigenesis. Journal of Pathology, 2021, 254, 279-288.	4.5	12
13	Organoids in cancer research: a review for pathologistâ€scientists. Journal of Pathology, 2021, 254, 395-404.	4.5	14
14	Early detection of pancreatic cancer using DNA-based molecular approaches. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 457-468.	17.8	67
15	Familial Adenomatous Polyposis–associated Traditional Serrated Adenoma of the Small Intestine. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1626-1632.	3.7	1
16	Insights into the origins of pancreatic cancer. Nature, 2021, 597, 641-642.	27.8	1
17	Opposing roles of the immune system in tumors. Science, 2021, 373, 1306-1307.	12.6	6
18	Prophylactic appendiceal retrograde intraluminal stent placement (PARIS). VideoGIE, 2021, 6, 552-554.	0.7	1

#	Article	IF	CITATIONS
19	Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. Pancreas, 2021, 50, 1267-1273.	1.1	18
20	Abstract PO-111: A human single-cell RNA sequencing atlas of pancreatic ductal adenocarcinoma enables harmonized cell type calling and comprehensive analyses of potential intercellular signaling. , 2021, , .		0
21	Abstract PO-121: Investigating the role of human cancer-associated fibroblasts in pancreatic cancer invasion using patient-derived PDAC organoids. , 2021, , .		0
22	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Annals of Surgery, 2020, 271, 566-573.	4.2	64
23	Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. Modern Pathology, 2020, 33, 639-647.	5.5	47
24	Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas andÂBile Duct. Gastroenterology, 2020, 158, 573-582.e2.	1.3	110
25	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nature Cancer, 2020, 1, 59-74.	13.2	124
26	Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. Archives of Pathology and Laboratory Medicine, 2020, 144, 808-815.	2.5	31
27	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30
28	Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation. Pancreas, 2020, 49, 999-1003.	1.1	20
29	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology, 2020, 33, 2544-2563.	5.5	23
30	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Cancer Discovery, 2020, 10, 1566-1589.	9.4	90
31	Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nature Communications, 2020, 11, 4085.	12.8	77
32	Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Cancer Research, 2020, 80, 2804-2817.	0.9	58
33	Threeâ€dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding. Journal of Pathology, 2020, 251, 400-410.	4.5	16
34	Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Modern Pathology, 2020, 33, 2026-2034.	5.5	9
35	The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discovery, 2020, 10, 792-805.	9.4	71
36	Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. Laboratory Investigation, 2020, 100, 1003-1013.	3.7	3

#	Article	IF	CITATIONS
37	Desmin and CD31 immunolabeling for detecting venous invasion of the pancreatobiliary tract cancers. PLoS ONE, 2020, 15, e0242571.	2.5	10
38	Some Morphology Frontiers of Dysplasia in the Tubular Gastrointestinal Tract. American Journal of Surgical Pathology, 2020, Publish Ahead of Print, e1-e14.	3.7	0
39	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Cancers, 2019, 11, 1152.	3.7	33
40	Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 2019, 178, 795-806.e12.	28.9	830
41	Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathologica Communications, 2019, 7, 139.	5.2	12
42	Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. Gastroenterology, 2019, 157, 1123-1137.e22.	1.3	82
43	The inverted appendix – a potentially problematic diagnosis: clinicopathologic analysis of 21 cases. Histopathology, 2019, 74, 853-860.	2.9	11
44	Why is pancreatic cancer so deadly? The pathologist's view. Journal of Pathology, 2019, 248, 131-141.	4.5	76
45	Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology, 2019, 156, 2041-2055.	1.3	52
46	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology, 2019, 156, 1905-1913.	1.3	47
47	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clinical Epigenetics, 2019, 11, 59.	4.1	106
48	Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. Pancreas, 2019, 48, 1225-1231.	1.1	2
49	Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM). American Journal of Surgical Pathology, 2019, 43, 1297-1302.	3.7	2
50	Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. Journal of Gastrointestinal Surgery, 2019, 23, 477-483.	1.7	8
51	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Modern Pathology, 2019, 32, 659-665.	5.5	20
52	Single ell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Journal of Pathology, 2019, 247, 347-356.	4.5	52
53	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. Pancreas, 2019, 48, 70-76.	1.1	11
54	A "Clearer―View of Pancreatic Pathology: A Review of Tissue Clearing and Advanced Microscopy Techniques. Advances in Anatomic Pathology, 2019, 26, 31-39.	4.3	19

#	Article	IF	CITATIONS
55	Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. Journal of Pathology, 2019, 247, 123-134.	4.5	32
56	IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut, 2018, 67, 1652-1662.	12.1	104
57	Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. American Journal of Pathology, 2018, 188, 1530-1535.	3.8	38
58	Analogous detection of circulating tumor cells using the AccuCyte [®] —CyteFinder [®] system and ISET system in patients with locally advanced and metastatic prostate cancer. Prostate, 2018, 78, 300-307.	2.3	19
59	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	4.3	37
60	Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. Human Pathology, 2018, 72, 127-134.	2.0	21
61	Cancerization of the Pancreatic Ducts. American Journal of Surgical Pathology, 2018, 42, 1556-1561.	3.7	32
62	Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4293-4303.	3.6	15
63	Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Modern Pathology, 2018, 31, 1532-1538.	5.5	20
64	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
65	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Human Pathology, 2018, 81, 157-165.	2.0	44
66	Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status. Annals of Surgery, 2018, 268, 408-420.	4.2	125
67	From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions. Journal of Pathology, 2018, 246, 395-404.	4.5	67
68	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics, 2017, 49, 358-366.	21.4	316
69	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
70	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 391-400.	2.8	39
71	Genetic analyses of isolated highâ€grade pancreatic intraepithelial neoplasia (HGâ€PanIN) reveal paucity of alterations in <i>TP53</i> and <i>SMAD4</i> . Journal of Pathology, 2017, 242, 16-23.	4.5	108
72	PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology, 2017, 71, 375-382.	2.9	18

#	Article	IF	CITATIONS
73	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	2.8	10
74	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	27.0	451
75	The Almost-Normal Liver Biopsy. American Journal of Surgical Pathology, 2017, 41, 1247-1253.	3.7	18
76	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgery, 2017, 266, 133-141.	4.2	106
77	Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2017, 266, 339-345.	4.2	93
78	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell, 2017, 32, 460-473.e6.	16.8	142
79	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	12.8	515
80	Pancreatic undifferentiated carcinoma with osteoclastâ€like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. Journal of Pathology, 2017, 243, 148-154.	4.5	79
81	<i>Neat1</i> is a p53-inducible lincRNA essential for transformation suppression. Genes and Development, 2017, 31, 1095-1108.	5.9	179
82	Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas, 2017, 46, 943-947.	1.1	26
83	Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 2681-2690.	7.0	91
84	Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology, 2017, 70, 549-557.	2.9	20
85	The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS ONE, 2017, 12, e0180181.	2.5	68
86	Different prognostic roles of tumor suppressor gene <i>BAP1</i> in cancer: A systematic review with metaâ€analysis. Genes Chromosomes and Cancer, 2016, 55, 741-749.	2.8	58
87	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 2016, 264, 1073-1081.	4.2	131
88	Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. Journal of Clinical Pathology, 2016, 69, 956-961.	2.0	30
89	Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hpb, 2016, 18, 236-246.	0.3	79
90	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine, 2016, 22, 497-505.	30.7	456

#	Article	IF	CITATIONS
91	Molecular Genetics of Pancreatic Neoplasms. Surgical Pathology Clinics, 2016, 9, 685-703.	1.7	12
92	Genetic Syndromes with Pancreatic Manifestations. Surgical Pathology Clinics, 2016, 9, 705-715.	1.7	18
93	Prospective identification of Helicobacter pylori in routine gastric biopsies without reflex ancillary stains is cost-efficient for our health care system. Human Pathology, 2016, 58, 90-96.	2.0	7
94	Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Surgery, 2016, 20, 1692-1698.	1.7	41
95	Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. Pancreatology, 2016, 16, 869-872.	1.1	3
96	The Changing Landscape of Pancreatic Pathology. Surgical Pathology Clinics, 2016, 9, xiii.	1.7	1
97	Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Human Pathology, 2016, 56, 93-100.	2.0	31
98	A robust nonlinear tissue-component discrimination method for computational pathology. Laboratory Investigation, 2016, 96, 450-458.	3.7	9
99	Pancreatic cancer. Lancet, The, 2016, 388, 73-85.	13.7	1,826
100	Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell, 2016, 29, 229-240.	16.8	147
101	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
102	Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. Cancer Prevention Research, 2016, 9, 265-274.	1.5	80
103	Pathology and Genetics of Syndromic Gastric Polyps. International Journal of Surgical Pathology, 2016, 24, 185-199.	0.8	35
104	Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. Oncotarget, 2016, 7, 66906-66921.	1.8	17
105	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. American Journal of Surgical Pathology, 2015, 39, 1730-1741.	3.7	626
106	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
107	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell, 2015, 161, 1345-1360.	28.9	175
108	Pathological and Molecular Evaluation of Pancreatic Neoplasms. Seminars in Oncology, 2015, 42, 28-39.	2.2	64

7

#	Article	IF	CITATIONS
109	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clinical Cancer Research, 2015, 21, 1944-1950.	7.0	85
110	Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1407-1419.	3.0	43
111	Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. Genome Research, 2015, 25, 1536-1545.	5.5	121
112	Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head and Neck, 2015, 37, 1642-1649.	2.0	66
113	Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer Journal of Clinical Oncology, 2015, 33, 11025-11025.	1.6	2
114	Very long-term survival in pancreatic cancer. Aging, 2015, 7, 360-361.	3.1	6
115	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	1.8	67
116	Pancreatic adenocarcinoma pathology: changing "landscape". Journal of Gastrointestinal Oncology, 2015, 6, 358-74.	1.4	50
117	Genomic Landscapes of Pancreatic Neoplasia. Journal of Pathology and Translational Medicine, 2015, 49, 13-22.	1.1	16
118	Multimodality imaging and radiological-pathological analysis of ethiodized oil: Imaging biomarker of tumor necrosis after TACE?. Journal of Clinical Oncology, 2015, 33, TPS503-TPS503.	1.6	0
119	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
120	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes and Cancer, 2014, 53, 15-24.	2.8	91
121	Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology, 2014, 273, 746-758.	7.3	98
122	Wholeâ€exome sequencing of pancreatic neoplasms with acinar differentiation. Journal of Pathology, 2014, 232, 428-435.	4.5	151
123	Pathology and genetics of pancreatic neoplasms with acinar differentiation. Seminars in Diagnostic Pathology, 2014, 31, 491-497.	1.5	59
124	Upper GI Tract Lesions in Familial Adenomatous Polyposis (FAP). American Journal of Surgical Pathology, 2014, 38, 389-393.	3.7	105
125	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nature Communications, 2014, 5, 5006.	12.8	149
126	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1170-1172.	21.4	247

#	Article	IF	CITATIONS
127	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget, 2014, 5, 2839-2852.	1.8	171
128	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, 2013, 45, 1470-1473.	21.4	564
129	Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Modern Pathology, 2013, 26, 1586-1593.	5.5	56
130	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships. Journal of Radiation Oncology, 2013, 2, 413-425.	0.7	74
131	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
132	Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, 458-459.	0.8	21
133	Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E364-E369.	3.6	213
134	Pancreatic Cancer Genomes: Toward Molecular Subtyping and Novel Approaches to Diagnosis and Therapy. Molecular Diagnosis and Therapy, 2013, 17, 287-297.	3.8	6
135	Lichenoid Esophagitis. American Journal of Surgical Pathology, 2013, 37, 1889-1894.	3.7	64
136	Exomic Sequencing of Four Rare Central Nervous System Tumor Types. Oncotarget, 2013, 4, 572-583.	1.8	69
137	Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma Journal of Clinical Oncology, 2013, 31, 285-285.	1.6	0
138	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. Journal of Clinical Oncology, 2013, 31, 4057-4057.	1.6	1
139	Pathology and Molecular Genetics of Pancreatic Neoplasms. Cancer Journal (Sudbury, Mass), 2012, 18, 492-501.	2.0	114
140	A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuroprotective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian Monkeys. PLoS ONE, 2012, 7, e39036.	2.5	59
141	Somatic mutations in the notch, NFâ€KB, PIK3CA, and hedgehog pathways in human breast cancers. Genes Chromosomes and Cancer, 2012, 51, 480-489.	2.8	58
142	Folate Receptor Alpha: A New Tool in the Diagnosis and Treatment of Lung Cancer. Oncotarget, 2012, 3, 668-669.	1.8	5
143	Mutations in <i>CIC</i> and <i>FUBP1</i> Contribute to Human Oligodendroglioma. Science, 2011, 333, 1453-1455.	12.6	485
144	Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics, 2011, 43, 828-829.	21.4	392

#	Article	IF	CITATIONS
145	Building mitotic chromosomes. Current Opinion in Cell Biology, 2011, 23, 114-121.	5.4	40
146	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . Science, 2011, 333, 1154-1157.	12.6	1,568
147	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
148	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
149	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16224-16229.	7.1	285
150	A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Research, 2007, 17, 1304-1318.	5.5	121
151	The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 2007, 318, 1108-1113.	12.6	3,049
152	The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science, 2006, 314, 268-274.	12.6	3,130
153	Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutation, 2006, 27, 1060-1061.	2.5	87